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We examined the burden of large, rare, copy-number variants (CNVs) in 192 individuals with renal hypodysplasia (RHD) and replicated
findings in 330 RHD cases from two independent cohorts. CNV distribution was significantly skewed toward larger gene-disrupting
events in RHD cases compared to 4,733 ethnicity-matched controls (p ¼ 4.8 3 1011). This excess was attributable to known and novel
(i.e., not present in any database or in the literature) genomic disorders. All together, 55/522 (10.5%) RHD cases harbored 34 distinct
known genomic disorders, which were detected in only 0.2% of 13,839 population controls (p ¼ 1.2 3 1058). Another 32 (6.1%)
RHD cases harbored large gene-disrupting CNVs that were absent from or extremely rare in the 13,839 population controls, identifying
38 potential novel or rare genomic disorders for this trait. Deletions at the HNF1B locus and the DiGeorge/velocardiofacial locus were
most frequent. However, the majority of disorders were detected in a single individual. Genomic disorders were detected in 22.5% of
individuals with multiple malformations and 14.5% of individuals with isolated urinary-tract defects; 14 individuals harbored two or
more diagnostic or rare CNVs. Strikingly, the majority of the known CNV disorders detected in the RHD cohort have previous associa-
tions with developmental delay or neuropsychiatric diseases. Up to 16.6% of individuals with kidney malformations had a molecular
diagnosis attributable to a copy-number disorder, suggesting kidney malformations as a sentinel manifestation of pathogenic genomic
imbalances. A search for pathogenic CNVs should be considered in this population for the diagnosis of their specific genomic disorders
and for the evaluation of the potential for developmental delay.Introduction
Congenital malformations of the kidney and urinary tract
are present in 3–7 out of 1,000 births,1,2 accounting for
23% of birth defects.3 These malformations account for
40%–50% of pediatric and 7% of adult end-stage renal
disease worldwide.4–6 Among these malformations, renal
aplasia, agenesis, hypoplasia, and dysplasia (referred to
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RHD, and mutations in genes (e.g., PAX2 [MIM 167409] or
HNF1B [MIM 189907]) associated with syndromic forms of
disease are detected in up to 10% of individuals with
kidney malformations.7–11 Moreover, many familial forms
of disease have been reported, and multiple loci have been
implicated.12–14 These data suggest that many individuals
with RHD have a specific genetic diagnosis that cannot
be discerned by clinical evaluation alone.
Recent studies have shown that copy-number variations
(CNVs) are a common feature of the human genome.15,16
Rare CNVs, identified by array-based technologies, have
been implicated in the pathogenesis of many develop-
mental disorders, such as neuropsychiatric diseases or
craniofacial malformations.17–22 It is not known whether
CNVs similarly contribute to congenital kidney defects.
We performed a large systematic survey of CNV burden in
childrenwith congenital renal agenesis and hypodysplasia.
Material and Methods
Cohorts
The discovery cohort (n ¼ 192) and the first replication cohort
(n ¼ 196) consisted of white European affected individuals re-
cruited from pediatric centers in Italy, Poland,Macedonia, Croatia,
and the Czech Republic (Table S1, available online). All cases were
unrelated.
Inclusion criteria included the presence of a primary renal-
parenchyma defect—such as renal agenesis, a congenital solitary
kidney or renal hypodysplasia (finding of a small or cystic kidney
for age)—documented by prenatal or postnatal imaging studies,
such as an ultrasound, a computed-tomography scan, or a renal
isotopic scan. Additional urinary-tract and extra-urinary-tract
defects were also documented. Additional detected urinary-tract
defects included vesicoureteral reflux, duplicated ureters, and ure-
teropelvic-junction obstruction. Extra-urinary-tract manifesta-
tions detected in the cohort included cardiac (e.g., atrial or ventric-
ular septal defects), gastrointestinal (e.g., pyloric stenosis or anal
atresia), neurologic (e.g., developmental delay or a seizure
disorder), genital (e.g., septate uterus), craniofacial (e.g., cleft
lip), and skeletal (e.g., brachydactyly) defects. A family history of
nephropathy was obtained.
The second replication cohort consisted of 134 multiethnic
North American individuals (63% white, 23% African American,
and 10% admixed [Table S1]) diagnosed with RHD at the Chil-
dren’s Hospital of Philadelphia (CHOP). Individuals were identi-
fied on the basis of International Statistical Classification of
Diseases and Related Health Problems version 9 (ICD-9) codes
from a cohort of over 31,638 children and young adults assembled
by the Center for Applied Genomics. Chart review and evaluation
of electronicmedical records were performed for further validation
of the ICD-9 codes.
The study was approved by the institutional review boards at
Columbia University and the University of Pennsylvania, as well
as local ethics review committees in Genoa, Brescia, Parma, Foggia
and Milan (Italy), Poznan (Poland), Skopje (Macedonia), Split
(Croatia), and Olomouc (Czech Republic).
Controls
The control group consisted of 13,839 anonymized adults and
children selected from six cohorts of European (80.4%), Asian988 The American Journal of Human Genetics 91, 987–997, Decemb(13.4%), and African American ancestry (6.1%) after stringent
quality control. These cohorts were genotyped on high-density Il-
luminaplatforms as cases or controls for genetic studies of complex
traits not related to any developmental phenotypes (Table S2).
Genotyping, CNV Detection, and Burden Analysis
Genomic DNA was purified from peripheral-blood samples
collected after informed consent. None of the 522 RHD cases
was screened for mutations in known genes, such as PAX2,
HNF1B, EYA1. Genome-wide genotyping for CNV analysis was
performed with different Illumina platforms (Hap550v1 or higher,
Illumina, see Table S3), and genotype calls and quality-control
analyses were performed with GenomeStudio v.2010.3 (Illumina)
and PLINK software.23
The CNV calls were determined with generalized genotyping
methods implemented in the PennCNV program.24 The CNVs
were mapped to the human reference genome hg18 and anno-
tated with UCSC RefGene and RefExon (CNVision program25).
On the basis of validation studies, we only included CNVs with
confidence scores > 30 in the analyses (see Supplemental Material
andMethods). CNV frequencies were calculated on the basis of the
entire control data set of 13,839 individuals. For the analysis of
overlapping events, CNVs were defined as identical if they fulfilled
three criteria: (1) same CNV state, (2)%30% difference in length,
and (3) >70% overlap in span. All CNVs with <70% overlap were
not considered identical.
To compare the burden of large, rare CNVs, we utilized a subset
of 4,733 controls matched for ethnicity and genotyping platform
to cases in the discovery cohort (Illumina Hap-550, 610-Quad or
660W). We selected 4,733 controls from the Glasgow-Malmo
Hypertension study, the CHOP CNV study, and the Parkinson
Disease in Ashkenazi Jewish populations study in order to exclude
individuals of African American, Asian, and Hispanic descent (see
Supplemental Material and Methods). Criteria for the inclusion of
CNVs for the burden analysis included: (1) confidence score > 30,
(2) number of SNPs per CNV > 5, (3) CNV size > 100 kb, (4) CNV
frequency < 1% in the total sample set, and (5) no overlap with
any known common (frequency > 1%) CNVs. We used Fisher’s
exact test (R v.2.12) for testing differences in the distributions of
CNV type and CNV size. In addition, we calculated CNV metrics
per genome and compared distributions by using nonparametric
statistics (the Mann-Whitney U test) and empirical p values. We
also examined the population frequency of the largest CNV per
genome by using a log-rank test (SPSS IBM v.19). The proportions
of cases and controls with the largest CNVs at a given threshold
were compared with Fisher’s exact test.
Finally, to address the potential confounding effects of popula-
tion stratification on CNV-burden analysis, we also performed
genetic matching of RHD cases with controls (see in Supplemental
Material andMethods and Tables S5 and S6). SNP genotyping data
from the discovery cohort of 192 RHD cases have been deposited
in the dbGaP repository under accession number phs000565.v1.1.
CNVAnnotation and Confirmation
We annotated all rare CNVs across public databases (Gene
Reviews, Decipher, Online Mendelian Inheritance in Man, and
PubMed) to identify known genomic disorders. To select novel,
rare events, we eliminated all CNVs that had identical overlaps
in controls or that were encompassed within larger CNVs present
at a frequency higher than 0.025% in controls. (In this study, we
use ‘‘novel’’ to describe those disorders and variants that, to the
best of our knowledge, are not present in any database or in theer 7, 2012
Table 1. Comparison of Global CNV Counts between 192 RHD
Cases and 4,733 Controls Matched for Ethnicity and Genotyping
Platform
Global CNV
Metrics
RHD Cases
(n ¼ 192)
Controls
(n ¼ 4,733)
p Value
(Exact Test)
Total number
of rare CNVs
ncnv ¼ 351 ncnv ¼ 7,970 -
Size Distribution of All CNVs
100–250 kb 168 (47.9%) 4,908 (61.6%) 4.8 3 1011
250–500 kb 107 (30.5%) 2,234 (28.0%)
500–1,000 kb 52 (14.8%) 673 (8.4%)
>1,000 kb 24 (6.8%) 155 (1.9%)
Size Distribution of All Deletions
100–250 kb 77 (56.2%) 3,251 (66.9%) 1.2 3 1011
250–500 kb 28 (20.4%) 1,238 (25.5%)
500–1,000 kb 16 (11.7%) 317 (6.5%)
>1,000 kb 16 (11.7%) 54 (1.1%)
Size Distribution of Gene-Disrupting Deletions
100–250 kb 41 (47.1%) 2,430 (65.6%) 7.9 3 1013
250–500 kb 20 (23.0%) 990 (26.7%)
500–1,000 kb 11 (12.6%) 240 (6.5%)
>1,000 kb 15 (17.2%) 47 (1.3%)
Size Distribution of All Duplications
100–250 kb 91 (42.5%) 1,657 (53.3%) 0.011
250–500 kb 79 (36.9%) 996 (32.0%)
500–1,000 kb 36 (16.8%) 356 (11.4%)
>1,000 kb 8 (3.7%) 101 (3.2%)
Size Distribution of Gene-Disrupting Duplications
100–250 kb 65 (43.9%) 1,255 (51.2%) 0.010
250–500 kb 44 (29.7%) 802 (32.7%)
500–1,000 kb 32 (21.6%) 295 (12.0%)
>1,000 kb 7 (4.7%) 97 (4.0%)
The following abbreviations are used: CNV, copy-number variant; and RHD,
renal hypodysplasia.
Figure 1. CNV Burden Comparison between Cases and Controls
(A) Distribution of large (>100 kb), rare (<1%) CNVs by size in 192
RHD cases and 4,733 controls matched for ethnicity and genotyp-
ing platform.
(B) Comparison of the largest CNV per genome shows enrichment
of larger events among RHD cases.
The y axis describes the proportion of individuals with CNV size
above each size threshold (x axis). Note that the y axis in (B) is
on an exponential scale. The p values for differences in the distri-
bution are indicated.literature.) Rare or novel CNVs were also annotated against
ECARUCA (European Cytogeneticists Association Register of
Unbalanced Chromosome Aberrations), a database of rare cytoge-
netic abnormalities.Results
CNV-Burden Analysis
The discovery and replication cohorts are described in
Tables S1–S3. CNV analysis identified all large, rare CNVs
(defined as size > 100 kb and frequency < 1% across the
entire population). To avoid the confounding effects of
ethnicity or genotyping platform on the CNV-burden anal-
ysis, we compared the discovery cohort to a subset of 4,733The Americancontrols matched for ethnicity and genotyping platform
(Table 1).
The frequency of rare CNVs was only nominally higher
in cases than in controls (77% versus 70%, p ¼ 0.036).
However, RHD cases were significantly enriched with
larger events (p ¼ 4.8 3 1011 [Table 1 and Figure 1A]).
The enrichment of large CNVs among cases was most
evident for gene-disrupting events (p ¼ 1.8 3 105) and
particularly for large deletions (p ¼ 7.9 3 1013 [Table
1]). For example, 29.2% of gene-disrupting deletions were
larger than 500 kb in cases, whereas only 7.3% were larger
than 500 kb in controls (Table 1).
To verify that the excess of large CNVs was not attribut-
able to a few cases with an unusually high CNV load, we
further calculated CNV burden per genome (Table 2).
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Table 2. Comparison of CNV Burden per Genome between 192 RHD Cases and 4,733 Controls Matched for Ethnicity and Genotyping
Platform
Cases
(n ¼ 192)
Controls
(n ¼ 4,733)
Asymptotic
p Valuea
Empiric
p Valueb OR (95% CI)
p Value
(Fisher exact)
Metric
Average CNV rate 1.83 1.68 0.13 0.21 - -
Average CNV size (median) in kb 366.1 (218.7) 197.1 (161.1) 1.5 3 106 <1 3 106 - -
Average largest CNV size (median) in kb 518.5 (289.6) 260.4 (178.5) 2.7 3 106 3.0 3 106 - -
Average total CNV span (median) in kb 868.1 (417.0) 476.1 (234.2) 2.1 3 105 1.9 3 105 - -
Distribution of the Largest CNV per Genome
Individuals with largest CNV size > 1,000 kb n ¼ 17 (18.9%) n ¼ 142 (3.0%) - - 3.14 (1.74–5.35) 1.4 3 104
Individuals with largest CNV size > 500 kb n ¼ 49 (29.5%) n ¼ 629 (13.3%) - - 2.24 (1.56–3.15) 8.8 3 106
Individuals with largest CNV size > 250 kb n ¼ 105 (54.7%) n ¼ 1,774 (37.5%) - - 2.01 (1.49–2.72) 2.2 3 106
The following abbreviations are used: OR, odds ratio; CI, confidence interval; and CNV, copy-number variant.
aNonparametric (Mann-Whitney U) test for quantitative variables, Poisson-rate ratio test for rates, and Fisher’s exact test for proportions.
bBased on 1,000,000 permutations.the CNV rate per genome was not different between cases
and controls (1.83 versus 1.68, p ¼ 0.21), but cases demon-
strated a significantly greater average CNV size (366.1 kb
versus 197.1 kb, p ¼ 1.5 3 106), average total CNV span
(868 kb versus 476 kb, p ¼ 2.1 3 105), and average largest
CNV size per genome (518.5 kb versus 260.4 kb, p¼ 2.713
106). Comparison of the largest CNV per genome showed
clear differences above the 250 kb threshold: 54.7% of
cases harbored a CNV greater than 250 kb, whereas only
37.5% of controls did (odds ratio ¼ 2.01, p ¼ 2.2 3 106
[Table 2 and Figure 1B]), suggesting that as much as
17.2% of RHD cases in this cohort is attributable to
CNVs larger than 250 kb.
The burden analysis was also repeated after we geneti-
cally matched the discovery cohort with a different set of
controls. This analysis confirmed a highly significant
excess of large CNVs among cases, demonstrating that
differences in CNV load are not due to population stratifi-
cation (see Supplementary Material and Methods, Tables
S4–S6, and Figures S1 and S2).
Moreover, we repeated the analysis by using only the
pediatric controls from the CHOP study. The results from
this analysis are nearly identical to the original findings
on the larger controls data set and the genetically matched
cohort that included adults, thereby ruling out bias due to
the inclusion of adult controls (see Table S7 and Figure S3).
Identification of Known Copy-Number Disorders
in 10.5% of RHD Cases
The consistent overrepresentation of large CNVs among
cases indicated the presence of genomic disorders. We
therefore annotated all large, rare CNVs that disrupted
coding segments in the discovery cohort and replicated
findings in two cohorts recruited from European (n ¼
196) and North American (n ¼ 134) medical centers.
All together, 55/522 RHD individuals (10.5%) in the
combined discovery and two replication cohorts harbored990 The American Journal of Human Genetics 91, 987–997, Decemba known genomic disorder for a total of 34 distinct, known
syndromes (Table 3 and Table S8).We identified CNVs diag-
nostic of 17 known genomic disorders in 25 (13%) cases in
the discovery cohort, 21 known genomic disorders in 18
(9.2%) individuals in the European replication cohort,
and 14 known genomic disorders in 12 (9%) cases in the
North American cohort (Table 3). The same disorders were
present in only 30 (0.2%) of 13,839 population controls
(Fisher exact p value¼ 1.23 1058 versus RHDcases). These
data independently confirm that genomic disorders repre-
sent a very common etiology for RHD (Table 3).
Thirteen disorders were detected across different cohorts
or affected individuals of different nationalities, impli-
cating independent events. Deletions at the HNF1B locus
in chromosomal region 17q11-12 and at the locus for Di-
George syndrome (DGS [MIM 188400]) and velocardiofa-
cial syndrome (VCFS [MIM 192430]) (hereafter called the
DGS/VCFS locus) in chromosomal region 22q11 were the
most frequent findings (11 and 4 cases, respectively).
However, themajority of disorders were detected in a single
individual, indicating significant genetic heterogeneity of
the trait.Wedetected four inherited andfivedenovo events
among the eight cases with parental DNA available in the
discovery cohort. Six cases, distributed across all three
cohorts, carried two known genomic imbalances. Twenty
(59%) diagnostic CNVs were flanked by segmental duplica-
tions, implicating nonallelic homologous recombination
as the underlying mechanism. Finally, genomic disorders
were detected in individuals with isolated RHD (n ¼ 31),
as well as in those withmultiorganmanifestations (n¼ 24).
Identification of Novel or Rare Copy-Number
Disorders in up to 6.1% of RHD
After exclusion of individuals with diagnostic CNVs, there
was still evidence of excess CNV burden among the RHD
cases (Table S9). We therefore searched for additional novel
or rare genomic disorders by identifying CNVs that wereer 7, 2012
larger than 100 kb, disrupted coding segments, and were
absent from or extremely rare in the 13,839 controls
(CNV frequency % 1:4,000).
All together, we identified 38 independent events fulfill-
ing these criteria in 32/522 cases (6.1% of the RHD cases,
Table S10), defining candidate novel genomic disorders.
Similar to the situation with known disorders, the majority
of imbalances were encountered in a single individual,
with or without multiorgan manifestations, and among
the 12 cases with parental DNA available, six CNVs
occurred de novo.
If we use highly conservative criteria—selecting only
CNVs that occurred de novo, were recurrent, or were larger
than 1 Mb—this analysis identified 15 rare or novel
genomic disorders (five recurrent duplications, three de
novo deletions, two de novo duplications, and four
CNVs > 1,000 kb, Table 4) in 20 RHD cases. This indicates
a lower bound of 3.8% for novel or rare genomic disorders
in the combined cohort.
Rare Intergenic and Single-Gene CNVs
We also searched for rare intergenic CNVs and CNVs dis-
rupting a single gene in the discovery cohort.We identified
27 intergenic CNVs and 13 single-gene-disrupting CNVs
that were absent in all 13,839 controls and in a recent
study that identified CNVs at a resolution reaching 1 kb
(Tables S12 and S13).26 These CNVs identify candidate
genes for RHD. For example, a gene-disrupting deletion
and an intergenic deletion identify EFEMP1 (RefSeq acces-
sion number NM_001039348; MIM 601548) as a potential
causal gene for RHD (Tables S12 and S13).
Annotation of Genes within CNVs
We examined phenotypes resulting from inactivation of
the murine orthologs of the genes located within the 72
known and candidate pathogenic CNVs. We identified
53 positional candidates whose inactivation results in
kidney developmental defects in mice, and there is at least
one gene implicated in kidney developmental defects in
32% of these CNV intervals (Table S8 and S10). For
example, disruption of murine orthologs of KIF26B (MIM
614026)25 and PBX1 (MIM 176310)26 leads to renal agen-
esis or hypoplasia, suggesting that these are most likely
the culprit genes within the de novo deletion in chromo-
somal regions 1q43-q44 and 1q32, respectively. Many of
these genes are associated with both renal and neurodeve-
lopmental defects, suggesting pleiotropism. For example,
inactivation of Fgfrl1 produces kidney and brain mor-
phological defects that recapitulate many of the
clinical features of Wolf-Hirschhorn syndrome (MIM
194190).27,28 The identification of credible candidate
genes within the majority of these loci further supports
the pathogenicity of the imbalances.
Clinical Correlations
There were no differences in gender, ethnicity, or family
history of nephropathy between individuals with orThe Americanwithout a genomic disorder. Deletions and duplications
were also similarly distributed between these two groups.
However, genomic disorders were detected more fre-
quently among cases with malformations outside the
urinary tract (32/142 [22.5%]) than among those with iso-
lated urinary-tract defects (55/380 [14.5%], Fisher’s exact
p ¼ 0.03 for comparison between the groups). Fourteen
individuals (2.7% of the RHD cohort), distributed across
all three cohorts, harbored two or more diagnostic or
rare CNVs; nine (64%) of these individuals manifested
multiorgan defects, consistent with their high CNV load
(Table S11). Among the cases with ten inherited CNVs,
four individuals had familial disease (the CNVs segregated
with disease in three of these individuals), and one had
parents with an unknown renal phenotype and an
unavailable affected sibling; therefore, the segregation
pattern is not discernible (Tables S8 and S10). Finally,
consistent with the identification of many positional
candidates involved in neurological defects, 90% of the
known imbalances listed in Table 3 are associated with
an increased risk of neuropsychiatric disease, such as
autism, schizophrenia, intellectual disability, or seizures
(e.g., 1q21 deletion [MIM 612474],21 2q37 deletion [MIM
600430],27 or Potocki-Lupski syndrome [MIM 610883]).28
Discussion
Nephrogenesis requires a complex sequence of mutually
inductive signals between two intermediate mesenchymal
progenitors: the metanephric mesenchyme and the
ureteric bud.29 Consistent with the complex signaling
cascade involved in this process, we identified very diverse
genetic lesions resulting in kidney developmental defects.
Our findings were robust to many alternative analyses and
were consistent across all three RHD cohorts, excluding an
analytic bias. The significant etiological heterogeneity of
congenital kidney malformations was not detectable by
clinical evaluation, and the fact that most of the structural
variants were below the resolution of standard cytogenetic
analysis indicates that high-resolution genomic methods
are required for identifying the specific etiology of disease
in the RHD population.
All together, we detected 72 distinct known or novel
genomic disorders in 16.6% of RHD cases (10.5% with
known disorders and 6.1% with rare or novel disorders),
indicating a large proportion of rare pathogenic imbal-
ances in this population. This number is consistent with
the CNV-burden analysis, which suggested that 17.2% of
RHD cases are attributable to CNVs larger than 250 kb
(Table 2). These data identify candidate genes or loci that
impart a large effect on RHD andmost likely disrupt critical
nodes in the renal developmental program. We detected
a single pathogenic imbalance in most individuals (only
2.7% of cases had two or more large CNVs), suggesting
a model of rare mutations with large effect. Among the
21 individuals with available parents, 11 (52%) had de
novo CNVs, whereas 10 (48%) had inherited structuralJournal of Human Genetics 91, 987–997, December 7, 2012 991
Table 3. Thirty-Four Known Genomic Disorders Identified in 522 RHD Cases
Chromosomal
Region
CNV
Type
Start
(Mb)
End
(Mb)
Size
(Mb) Syndrome
Discovery
(n ¼ 192)
Replication 1
(n ¼ 196)
Replication 2
(n ¼ 134)
Combined
(n ¼ 522)
Controls
(n ¼ 13,839) p Value
Prior Association
with RHD/
Neuropsychiatric Traits?
1p36 dup 2.91 3.65 0.74 1p36 dup 0 0 2 2 0 1.32 3 103 N/Y
1p22 dup 89.50 89.97 0.47 1p22.2-p31.1 dupa 0 1 1 2 0 1.32 3 103 N/Y
1q21 del 144.11 144.63 0.52 1q21 TAR delb 1 0 0 1 1 0.071 Y/Y
1q21 del 144.80 145.86 1.06 1q21 distal delb 1 3 0 4 4 1.07 3 104 Y/N
1q43-q44 del 240.61 245.67 5.06 1q43-q44 del 1 0 0 1 0 0.036 Y/Y
2q37 dup 240.99 242.44 1.45 2q37 dupc 0 1 0 1 0 0.036 Y/Y
3p26 dup 1.35 2.18 0.83 3pter-p25 del 2 0 0 2 8 0.049 N/Y
4p16 del 0.06 17.29 17.23 Wolf-Hirschhornd 0 1 1 2 0 1.32 3 103 Y/Y
5p15 dup 0.11 10.96 10.85 5p distal dupd 0 0 1 1 0 0.036 Y/Y
5q14-q23 del 91.46 114.55 23.09 5q interstitial del 0 0 1 1 0 0.036 N/Y
6q13-q14 dup 70.29 70.76 0.47 6q13-q14 del 1 0 0 1 0 0.036 Y/Y
7p22 dup 6.82 7.27 0.45 7p interstitial dup 0 0 1 1 0 0.036 Y/Y
7p21 dup 16.80 17.71 0.91 7p interstitial dup 0 0 1 1 1 0.071 Y/Y
7p15 del 23.68 27.43 3.75 7p15.1-p21.1 del 0 1 0 1 0 0.036 Y/N
7q34-q36 del 141.53 158.81 17.28 7q36 del 1 0 1 2 0 1.32 3 103 Y/Y
8p23 dup 8.13 11.94 3.81 8p23.1 dup 1 0 0 1 1 0.071 Y/Y
9p22e del 14.81 14.97 0.17 9p22.3 del 0 1 0 1 0 0.036 N/N
16p13 dup 0.04 15.09 15.04 16p subtelomeric
dupf
0 1 0 1 0 0.036 Y/Y
16p13 dup 15.03 15.80 0.77 16p13.11 dup 1 0 0 1 5 0.199 N/Y
16p11 del 29.55 31.86 2.31 16p11.2 distal del 0 2 0 2 0 1.32 3 103 Y/Y
16p11 dup 29.50 30.05 0.55 16p11.2 distal dup 0 0 1 1 3 0.138 N/Y
17p11-p12 dup 16.41 20.23 3.82 Potocki-Lupski
syndrome
1 0 1 2 0 1.32 3 103 Y/Y
17q11-q12 del 31.89 33.35 1.46 renal cysts and
diabetes (HNF1B)g
5 5 1 11 0 1.32 3 1016 Y/Y
17q11-q12 dup 31.89 33.25 1.36 17q12 dup (HNF1B) 1 0 0 1 1 0.071 Y/Y
17q21 del 40.94 41.41 0.47 17q21.31 del 1 0 0 1 2 0.105 Y/Y
20p11-p13 dup 0.11 24.77 24.66 20p partial trisomya 0 1 0 1 0 0.036 Y/Y
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Table 3. Continued
Chromosomal
Region
CNV
Type
Start
(Mb)
End
(Mb)
Size
(Mb) Syndrome
Discovery
(n ¼ 192)
Replication 1
(n ¼ 196)
Replication 2
(n ¼ 134)
Combined
(n ¼ 522)
Controls
(n ¼ 13,839) p Value
Prior Association
with RHD/
Neuropsychiatric Traits?
21q22 del 40.51 46.91 6.40 21q partial monosomy 0 0 1 1 0 0.036 N/Y
22q11 dup 15.29 18.61 3.32 22q11.2 dup
(VCFS region)c
0 1 0 1 0 0.036 Y/Y
22q11 del 17.27 19.79 2.52 DiGeorge/VCFS del 3 1 0 4 0 1.73 3 106 Y/Y
22q13 del 42.94 49.52 6.58 Phelan-McDermid
syndromef,g
0 1 1 2 0 1.32 3 103 Y/Y
X gain XXY XXY - Klinefelter syndrome 1 0 0 1 0 0.044 Y/Y
Xp22 del 6.46 8.10 1.64 Xp22.31 del 2 0 0 2 0 1.92 3 103 Y/Y
Xp22 dup 8.19 8.67 0.48 Kallman syndrome
region (KAL1)
2 1 0 3 4 1.5 3 103 Y/Y
Xq27 dup 139.36 139.91 0.55 mental retardation
with panhypopituitarism
syndrome
1 0 0 1 0 0.044 N/Y
Total number of known pathogenic CNVs 26 21 14 61 30 9.9 3 1066 -
Total number of individuals with at least one pathogenic CNV 25 (13%) 18 (9.2%) 12 (9%) 55 (10.5%) 30 (0.21%) 1.22 3 1058 -
CNV start and end positions are based on UCSC genome build hg18. The symbol for the causal gene at each locus is indicated when known. Fisher’s exact p values for comparison of CNV frequency between combined cohorts
(n ¼ 522) and controls (n ¼ 13,839) are indicated. The last row compares the total number of individuals carrying at least one of the CNVs listed in this table (Fisher’s exact test). The following abbreviations are used:
CNV, copy-number variation; RHD, renal hypodysplasia; dup, duplication; del, deletion; N, no; Y, yes; and VCFS, velocardiofacial syndrome.
a–d,f,gSix individuals, corresponding to letters a–d, f, and g, were each diagnosed with two of these syndromes (e.g. ‘‘a’’ indicates that one individual had a 1p22.2-p31.1 deletion and 20p partial trisomy). Additional infor-
mation and references are reported in Table S8.
eHomozygous FREM1 mutations within this locus produce bifid nose with or without anorectal and renal anomalies (BNAR [MIM 608980]), but heterozygous mutations are only associated with isolated craniosynostosis
(Vissers et al. in Table S8).
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Table 4. Fifteen Novel or Rare Genomic Disorders Identified in 522 RHD Cases on the Basis of the Strictest Criteria
Chromosomal
Region
CNV
Type
Start
(Mb)
End
(Mb)
Size
(Mb) Inheritance
Discovery
(n ¼ 192)
Replication 1
(n ¼ 196)
Replication 2
(n ¼ 134)
Combined
(n ¼ 522)
Controls
(n ¼ 13,839) p Value
1q32 del 162.68 163.19 0.51 de novo 1 0 0 1 0 0.036
2p25 dup 0.02 3.65 3.63 N/A 1 0 1 2 0 1.32 3 103
2p11 dup 88.16 89.24 1.08 N/A 0 0 1 1 0 0.036
3q13-q22 del 118.15 133.11 14.96 de novo 1 0 0 1 0 0.036
3q29 dup 199.17 199.32 0.15 N/A 1 1 0 2 3 0.012
4p13 dup 44.12 44.75 0.63 de novo 1 0 0 1 0 0.036
5q34 dup 159.53 160.58 1.05 N/A 0 2 0 2 0 1.32 3 103
7q21 del 79.33 80.91 1.58 N/A 0 1 0 1 0 0.036
10p11 dup 42.10 42.71 0.61 N/A 2 0 0 2 0 1.32 3 103
11p11 dup 49.58 50.52 0.94 N/A 0 2 0 2 1 3.86 3 103
12q24 dup 124.67 132.29 7.52 de novo 1 0 0 1 0 0.036
13q11 del 22.44 23.80 1.36 de novo 1 0 0 1 3 0.138
13q12 dup 36.28 37.51 1.23 inherited 1 0 0 1 0 0.036
16q22 del 73.39 73.90 0.51 de novo 1 0 0 1 0 0.036
17q25 dup 71.00 78.63 7.63 N/A 0 0 1 1 0 0.036
CNV start and end positions are based on UCSC genome build hg18. These rare CNVs were selected on the basis of a frequency < 0.025% in controls and occur-
rence inR 2 RHD cases or on the basis of de novo status or a size> 1 Mb. A complete list of novel, rare CNVs and additional information are reported in Table S10.
The following abbreviations are used: CNV, copy-number variation; del, deletion; dup, duplication; and N/A, not available.variants, suggesting incomplete penetrance in this second
group. Strikingly, 90% of the known disorders detected in
our study have been shown to predispose to develop-
mental delay or neuropsychiatric disease, suggesting
shared pathways between renal and neural developmental
programs.
Rearrangements in chromosomal region 17q12 were the
most common genomic disorders detected in the cohort
and accounted for 2.3% of cases.30,31 HNF1B mutations,
resulting in renal cysts and diabetes, are the cause of
RHD at this locus. This finding is consistent with prior
studies showing that HNF1B mutations are a common
cause of RHD and that RHD is the most consistent and
earliest manifestation of this syndrome, whereas addi-
tional phenotypes, such as diabetes or hyperuricemia,
develop at a later age.8,9,11,32 Neuropsychiatric disease is
also an increasingly recognized complication of rearrange-
ments in chromosomal region 17q12.33,34 DGS/VCFS was
the next most frequent disorder, consistent with the
known occurrence of urologic defects in nearly 40% of
individuals with this syndrome.30,31 Disruption of
different genes within the DGS/VCFS locus is thought to
account for the spectrum of developmental, metabolic,
and immunologic defects in this syndrome, but the
specific genetic lesion(s) responsible for the kidney malfor-
mations have not been clarified. Our study identified dele-
tions in the distal 370 kb region of the DiGeorge locus (the
LCRC-LCRD region) in three cases with isolated RHD, sug-
gesting that the gene responsible for the urinary-tract
defects is located in this segment. The other known994 The American Journal of Human Genetics 91, 987–997, Decembsyndromes occurred mostly as singleton cases. Of clinical
importance, about half of the individuals with these
copy-number disorders presented with isolated RHD, sug-
gesting that kidney defects might be an early or sensitive
manifestation of pathogenic genomic imbalances.
In addition to known syndromes, we also identified
large, rare, gene-disrupting CNVs in another 32 individuals
(6.1% of the cohort [Table 4 and Table S10]). We found
evidence of 15 recurrent, de novo, or large events in 20
individuals, indicating a lower bound of 3.8% for novel
or rare genomic disorders. These novel or rare CNVs share
many common characteristics with the diagnostic CNVs
discovered in this cohort: they have a similar proportion
of deletions, duplications, and de novo events but were
slightly smaller and less frequently flanked by segmental
duplications, suggesting that many arise frommechanisms
other than nonallelic homologous recombination. Finally,
we identified many unique intergenic and single-gene-
disrupting CNVs. These findings offer a list of candidate
genes and genomic disorders that can be confirmed in
independent human cohorts or via the creation of animal
models. For example, we found two rare events involving
EFEMP1, a member of the fibulin family of extracellular-
matrix glycoproteins. Although a single amino acid substi-
tution (p.Arg345Trp) has been associated with Malattia
Leventinese and Doyne honeycomb retinal dystrophy in
humans,35 targeted disruption in mice does not produce
a retinal phenotype but rather a widespread aging pheno-
type with early kidney atrophy.36 Thus, loss-of-function
mutations in humans could result in early arrest of kidneyer 7, 2012
growth and atrophy, causing reduced kidney size (that can
be diagnosed as renal hypoplasia) in childhood.
Our findings are comparable to a recent study showing
that diverse pathogenic CNVs account for 14.2% of disease
in a large series of children with developmental delay
and/or intellectual disability and variable organ malforma-
tions.20 However, only 13 of the 34 known genomic
disorders detected in the present study overlap with those
identified by Cooper et al.,20 indicating both shared and
distinct genetic lesions between these two traits. Our
findings suggest that similar to neural development, neph-
rogenesis is very sensitive to variation in gene dosage, and
the presence of kidney malformations should alert clini-
cians to the possibility of pathogenic genomic imbalances.
Because kidney malformations can be detected prenatally
or at birth, a CNV screen might identify the potential for
complications such as developmental delay, autism, or
cognitive defects before they become clinically evident.
In addition to informing family discussions, identification
of RHD-affected individuals with genomic imbalances can
better define the burden and trajectory of disease in this
subgroup. Finally, this study offers a list of candidate genes
and loci that can help dissect the complex signaling
pathway required for nephrogenesis.
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